Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bupivacaine extended release - Pacira BioSciences

Drug Profile

Bupivacaine extended release - Pacira BioSciences

Alternative Names: Bupivacaine extended-release - Pacira BioSciences; Bupivacaine extended-release liposome injection; Bupivacaine liposome extended-release injectable suspension; Bupivacaine liposome injectable suspension; DepoBupivacaine; Exparel; SKY-0402

Latest Information Update: 17 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator SkyePharma Inc
  • Developer Pacira BioSciences; Pacira Pharmaceuticals
  • Class Anilides; Local anaesthetics; Non-opioid analgesics; Pipecolic acids; Piperidines; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Anaesthesia; Postoperative pain
  • Phase III Dental pain
  • No development reported Musculoskeletal pain; Pain

Most Recent Events

  • 25 Nov 2019 Pacira Pharmaceuticals plans a phase I trial for in healthy volunteers in January 2020 (NCT04173611)
  • 08 Nov 2019 Nuance Pharma plans a phase I trial in healthy volunteers in November 2019 (NCT04158102)
  • 24 Sep 2019 Pacira Pharmaceuticals completes the phase III PLAY trial for Postoperative pain (In children, In adolescents) in USA (Infiltration) (NCT03682302)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top